Versantis is focused on liver disease and develops VS-01 for hepatic encephalopathy in patients with decompensated cirrhosis. Its lead candidate, VS-01, is entering the Ph.1b clinical stage in 2019. It was granted Orphan Drug Designations (FDA/EMA) which will expedite its overall clinical program.
